Quarterly report pursuant to Section 13 or 15(d)

Collaboration and Research Arrangements - Schedule of Change in Accounts Receivable, Contract Assets and Liabilities (Details)

v3.22.2
Collaboration and Research Arrangements - Schedule of Change in Accounts Receivable, Contract Assets and Liabilities (Details)
$ in Thousands
 6 Months Ended
Jun. 30, 2022
USD ($)
Disaggregation Of Revenue [Line Items]  
Accounts receivable and contract assets, Balance at Beginning of Period $ 2,979
Accounts receivable and contract assets, Additions 11,546
Accounts receivable and contract assets, Deductions (12,233)
Accounts receivable and contract assets, Balance at End of Period 2,292
Contract liabilities, Balance at Beginning of Period 10,181
Contract liabilities, Additions 45
Contract liabilities, Deduction (6,635)
Contract liabilities, Balance at End of Period 3,591
Incyte  
Disaggregation Of Revenue [Line Items]  
Contract liabilities, Balance at Beginning of Period 1,268
Contract liabilities, Deduction (1,042)
Contract liabilities, Balance at End of Period 226
Global Blood Therapeutics  
Disaggregation Of Revenue [Line Items]  
Contract liabilities, Balance at Beginning of Period 8,913
Contract liabilities, Additions 45
Contract liabilities, Deduction (5,593)
Contract liabilities, Balance at End of Period 3,365
Billed receivables from collaboration partners  
Disaggregation Of Revenue [Line Items]  
Accounts receivable, Additions 5,841
Accounts receivable, Deduction (5,841)
Unbilled receivables from collaboration partners  
Disaggregation Of Revenue [Line Items]  
Contract assets, Balance at Beginning of Period 2,979
Contract assets, Additions 5,705
Contract assets, Deduction (6,392)
Contract assets, Balance at End of Period $ 2,292